Cellebrite DI - CLBT Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $13.17
  • Forecasted Upside: 5.84%
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$12.44
▼ -0.06 (-0.48%)

This chart shows the closing price for CLBT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Cellebrite DI Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CLBT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CLBT

Analyst Price Target is $13.17
▲ +5.84% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Cellebrite DI in the last 3 months. The average price target is $13.17, with a high forecast of $16.00 and a low forecast of $9.00. The average price target represents a 5.84% upside from the last price of $12.44.

This chart shows the closing price for CLBT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 6 polled investment analysts is to buy stock in Cellebrite DI. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/21/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/21/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/19/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/17/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/16/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/15/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/14/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/13/2024

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/24/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$12.00 ➝ $14.00Low
5/24/2024Needham & Company LLCBoost TargetBuy ➝ Buy$13.50 ➝ $14.00Low
4/19/2024Lake Street CapitalInitiated CoverageBuy$13.00Low
4/1/2024Craig HallumBoost TargetBuy ➝ Buy$14.00 ➝ $16.00Low
4/1/2024Bank of AmericaBoost TargetBuy ➝ Buy$12.00 ➝ $13.00Low
3/28/2024Needham & Company LLCBoost TargetBuy ➝ Buy$13.00 ➝ $13.50Low
3/13/2024William BlairUpgradeMarket Perform ➝ OutperformLow
2/16/2024Bank of AmericaUpgradeNeutral ➝ Buy$9.00 ➝ $12.00Low
2/15/2024Needham & Company LLCBoost TargetBuy ➝ Buy$10.00 ➝ $13.00Low
8/30/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$10.00Low
8/9/2023Needham & Company LLCBoost TargetBuy ➝ Buy$7.00 ➝ $10.00Low
8/9/2023JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$8.00 ➝ $10.00N/A
8/9/2023Deutsche Bank AktiengesellschaftBoost Target$6.50 ➝ $9.00Low
7/19/2023Craig HallumInitiated CoverageBuy$11.00Low
6/16/2023Bank of AmericaBoost Target$6.15 ➝ $6.75Low
3/14/2023Needham & Company LLCBoost TargetBuy$6.50 ➝ $7.00Low
2/16/2023Needham & Company LLCReiterated RatingBuy$6.50Low
8/12/2022Bank of AmericaDowngradeBuy ➝ Neutral$6.50 ➝ $6.00Low
8/12/2022CowenLower TargetOutperform$13.00 ➝ $10.00Low
8/12/2022CowenLower TargetOutperform$13.00 ➝ $10.00Low
8/12/2022William BlairDowngradeOutperform ➝ Market PerformLow
8/11/2022Needham & Company LLCBoost TargetBuy$6.00 ➝ $6.50Low
5/16/2022CowenLower Target$17.00 ➝ $13.00High
5/13/2022Deutsche Bank AktiengesellschaftLower Target$11.00 ➝ $10.00High
2/24/2022JPMorgan Chase & Co.Initiated CoverageOverweight$10.50High
2/17/2022CowenLower Target$20.00 ➝ $17.00Low
2/17/2022Deutsche Bank AktiengesellschaftBoost Target$10.50 ➝ $11.00Medium
2/11/2022Deutsche Bank AktiengesellschaftInitiated CoverageBuy$10.50Low
12/29/2021Needham & Company LLCLower TargetBuy$12.00 ➝ $9.50High
12/2/2021Bank of AmericaInitiated CoverageBuy$11.00High
10/20/2021CitigroupInitiated CoverageBuy$15.00High
9/29/2021Needham & Company LLCInitiated CoverageBuy$12.00Low
9/24/2021William BlairInitiated CoverageOutperformMedium
9/13/2021CowenInitiated CoverageOutperform$20.00Medium
(Data available from 6/13/2019 forward)

News Sentiment Rating

0.90 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 7 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/16/2023
  • 2 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
12/16/2023
  • 6 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/15/2024
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/14/2024
  • 13 very positive mentions
  • 19 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/15/2024
  • 4 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/14/2024
  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/14/2024
  • 9 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/13/2024

Current Sentiment

  • 9 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Cellebrite DI logo
Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft. It provides Inseyets, a digital forensics software that collects and reviews digital evidence from various digital sources when conducting legally sanctioned investigations. The company's digital forensics software also offers data extraction, decoding capabilities, workflows, and automation capabilities. In addition, it provides Cellebrite Pathfinder, which reduces the time spent manually reviewing digital evidence by automating data analysis and visualization; Smart Search, an open source intelligence tool that automates the collection and review of publicly available online data; and Guardian, a case and evidence management solution. Further, the company offers digital forensic software for enterprises and service providers, including Inseyets for Enterprise, Endpoint Inspector, and Mobile Now; and professional services, such as training and certification services, and other services. It serves federal and state and local agencies. The company was incorporated in 1999 and is headquartered in Petah Tikva, Israel.
Read More

Today's Range

Now: $12.44
Low: $12.32
High: $12.64

50 Day Range

MA: $11.01
Low: $10.38
High: $12.50

52 Week Range

Now: $12.44
Low: $6.08
High: $12.64

Volume

266,363 shs

Average Volume

920,514 shs

Market Capitalization

$2.56 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.48

Frequently Asked Questions

What sell-side analysts currently cover shares of Cellebrite DI?

The following equities research analysts have issued stock ratings on Cellebrite DI in the last twelve months: Bank of America Co., Craig Hallum, Deutsche Bank Aktiengesellschaft, JPMorgan Chase & Co., Lake Street Capital, Needham & Company LLC, TheStreet, and William Blair.
View the latest analyst ratings for CLBT.

What is the current price target for Cellebrite DI?

6 Wall Street analysts have set twelve-month price targets for Cellebrite DI in the last year. Their average twelve-month price target is $13.17, suggesting a possible upside of 5.3%. Craig Hallum has the highest price target set, predicting CLBT will reach $16.00 in the next twelve months. Deutsche Bank Aktiengesellschaft has the lowest price target set, forecasting a price of $9.00 for Cellebrite DI in the next year.
View the latest price targets for CLBT.

What is the current consensus analyst rating for Cellebrite DI?

Cellebrite DI currently has 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CLBT will outperform the market and that investors should add to their positions of Cellebrite DI.
View the latest ratings for CLBT.

What other companies compete with Cellebrite DI?

Other companies that are similar to Cellebrite DI include Paycom Software, Informatica, AppFolio, Confluent and Duolingo. Learn More about companies similar to Cellebrite DI.

How do I contact Cellebrite DI's investor relations team?

Cellebrite DI's physical mailing address is Four Embarcadero Center Suite 2100, SAN FRANCISCO CA, 94111. The company's listed phone number is 972-73-394-8000 and its investor relations email address is [email protected]. The official website for Cellebrite DI is www.cellebrite.com. Learn More about contacing Cellebrite DI investor relations.